Compound Detail
CHEMBL4297507
DELGOCITINIB 🧪 Phase III
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase III
Basic Information
| ChEMBL ID | CHEMBL4297507 |
| Name | DELGOCITINIB |
| Phase | Phase III |
| Structure Type | MOL |
| InChI Key | LOWWYYZBZNSPDT-ZBEGNZNMSA-N |
12
Targets
38
Activities
1
Assay Types
15
PK Parameters
20
Publications
7
Known Names
5
Indications
1
Mechanisms
Molecular Properties
310.4
MW (Da)
1.30
ALogP
5
HBA
1
HBD
88.9
PSA (Ų)
0.90
QED
0
Ro5 Violations
2
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Janus Kinase (JAK) inhibitor | INHIBITOR | Janus Kinase (JAK) | ✓ | ✓ |
Indications
Eczema Alopecia Areata Dermatitis, Atopic Lupus Erythematosus, Discoid Psoriasis
ATC Classification
D11AH11
delgocitinib
Level 1: DERMATOLOGICALS
Level 2: OTHER DERMATOLOGICAL PREPARATIONS
Activity Summary
IC50 38 meas. best 8.59
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Tyrosine-protein kinase JAK2 CHEMBL2971 | IC50 | 8.59 | 8.0517 | 2.6 | 6 |
| Tyrosine-protein kinase JAK1 CHEMBL2835 | IC50 | 8.55 | 8.45 | 2.8 | 5 |
| JAK3/JAK1 CHEMBL3038491 | IC50 | 8.05 | 7.6225 | 9.0 | 4 |
| Unchecked CHEMBL612545 | IC50 | 8.05 | 8.05 | 8.9 | 1 |
| T-cell CHEMBL614309 | IC50 | 8.05 | 8.05 | 8.9 | 1 |
| Tyrosine-protein kinase JAK3 CHEMBL2148 | IC50 | 7.89 | 7.71 | 13.0 | 5 |
| JAK1/TYK2 CHEMBL3301391 | IC50 | 7.75 | 7.5033 | 18.0 | 3 |
| Signal transducer and activator of transcription 3 CHEMBL4026 | IC50 | 7.75 | 7.246 | 18.0 | 5 |
| JAK2/JAK1 CHEMBL3038492 | IC50 | 7.6 | 7.54 | 25.0 | 2 |
| Non-receptor tyrosine-protein kinase TYK2 CHEMBL3553 | IC50 | 7.24 | 7.1375 | 58.0 | 4 |
| JAK2/TYK2 CHEMBL3301392 | IC50 | 7.08 | 7.08 | 84.0 | 1 |
| Tyrosine-protein kinase Lck CHEMBL258 | IC50 | 5.24 | 5.24 | 5800.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 4.833 | mL.min-1.kg-1 | Macaca mulatta |
| CL | 35.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 6.167 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 25.0 | mL.min-1.g-1 | Homo sapiens |
| CL | 25.0 | mL.min-1.g-1 | Homo sapiens |
| Cmax | 8.055 | nM | Rattus norvegicus |
| Cmax | 6.122 | nM | Canis lupus familiaris |
| F | 78.0 | % | Rattus norvegicus |
| F | 124.0 | % | Canis lupus familiaris |
| MRT | 1.0 | hr | Rattus norvegicus |
| MRT | 3.2 | hr | Canis lupus familiaris |
| T1/2 | 1.7 | hr | Rattus norvegicus |
| T1/2 | 2.3 | hr | Canis lupus familiaris |
| Tmax | 1.5 | hr | Rattus norvegicus |
| Tmax | 0.9 | hr | Canis lupus familiaris |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine